Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Study of proliferation in the mammary epithelium of young women using combined oral contraceptives
ISRCTN ISRCTN59588862
ClinicalTrials.gov identifier
Public title Study of proliferation in the mammary epithelium of young women using combined oral contraceptives
Scientific title
Acronym EPEMAHO (Estudo da Proliferacao no Epitelio da Mama de usuarias de Anticoncepcional Hormonal Oral)
Serial number at source 685/000
Study hypothesis Combined Oral Contraceptives (COC) affect the proliferation rate of mammary epithelium in young women (below 36 years of age) to a greater degree than older women.
Ethics approval This study, at the time of registration, received appropriate ethics committee approval from the Health Ministry of Brazil and the National Committee of Research Ethics on December 12, 2000.
Study design Randomised controlled trial
Countries of recruitment Brazil
Disease/condition/study domain Fibroadenoma
Participants - inclusion criteria 1. Females between 14 to 36 years of age
2. Undergoing excision of Fibroadenomas (FA) (a condition thought not to be associated with an increase risk of cancer) at the Department of Gynecology, Mastology Division: Benign mammary diseases, Federal University of São Paulo, Paulista Medical School
3. Signed an informed consent before enrolment in the study
4. Regular menstrual cycles (intervals of 28 ± two days) in the previous six months
5. A known date of the last menstrual period
Participants - exclusion criteria 1. Use of hormone therapy in the previous 12 months
2. Pregnancy
3. Breast feeding during the previous 12 months
4. Any endocrine disorder
5. Taking any medication at the time that tissue for the study was obtained
Anticipated start date 23/11/2000
Anticipated end date 15/12/2004
Status of trial Completed
Patient information material
Target number of participants 82 patients
Interventions Goal:
To determine the impact of one cycle of a combined oral contraceptive on breast homeostasis, we evaluated the Proliferation Index (PI), determined by the expression of KI-67, in normal human mammary epithelial cells and correlated it with cellular proliferation in spontaneous menstrual cycles during the same period.

Methods:
Normal breast tissue samples were obtained from 82 patients who were randomised in two groups:
Group A - Forty two women received one cycle of a Combined Oral Contraceptive (COC) (30 µg ethinyl estradiol and 150 µg levonorgestrel) administrated daily for 21 days, beginning on the first day of the menstrual cycle.
Group B - Forty patients experienced a natural menstrual cycle. No placebo was given.
Excision of the fibroadenoma then took place.

Menstrual cycle phase characterisation was based on the date of the last period and subsequent menses, and on progesterone serum levels obtained just before the time of biopsy.
Primary outcome measure(s) Successful excision of fibroadenoma; the histologically normal tissue (at least 1 cm away from the FA) was studied in women with COC and with natural cycles during the first, second, third and fourth week of the menstrual cycle.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding 1. Federal University of Sao Paulo and Health Ministry of Brazil (Brazil)
2. The National Commission of Ethics in Research (Comissao Nacional de Etica em Pesquisas [CONEP]) (Brazil) (registration number: 685/000)
Trial website
Publications 2008 results in http://www.ncbi.nlm.nih.gov/pubmed/18657146
Contact name Dr  Maria Alicia  Navarrete
  Address Rua Jose Maria Lisboa
1036 apto 111
  City/town Sao Paulo
  Zip/Postcode 01423000
  Country Brazil
  Tel +55 (11) 3088 0096
  Email chile@stanford.edu
Sponsor Federal university of Sao Paulo (Universidade Federal de Sao Paulo) (Brazil)
  Address Escola Paulista de Medicina
Rua Botucatu
740 - Vila Clementino
  City/town Sao Paulo
  Zip/Postcode 01454-010
  Country Brazil
  Tel +55 (11) 570 3321
  Fax +55 (11) 570 8715
  Email dgnarvaiza@intertim.com.br
  Sponsor website: http://www.unifesp.br/
Date applied 11/11/2006
Last edited 01/10/2008
Date ISRCTN assigned 14/12/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central